204 related articles for article (PubMed ID: 33133063)
1. POTN: A Human Leukocyte Antigen-A2 Immunogenic Peptides Screening Model and Its Applications in Tumor Antigens Prediction.
Meng Q; Wu Y; Sui X; Meng J; Wang T; Lin Y; Wang Z; Zhou X; Qi Y; Du J; Gao Y
Front Immunol; 2020; 11():02193. PubMed ID: 33133063
[TBL] [Abstract][Full Text] [Related]
2.
Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
5. Structure Based Prediction of Neoantigen Immunogenicity.
Riley TP; Keller GLJ; Smith AR; Davancaze LM; Arbuiso AG; Devlin JR; Baker BM
Front Immunol; 2019; 10():2047. PubMed ID: 31555277
[TBL] [Abstract][Full Text] [Related]
6. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
7. High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.
Blaha DT; Anderson SD; Yoakum DM; Hager MV; Zha Y; Gajewski TF; Kranz DM
Cancer Immunol Res; 2019 Jan; 7(1):50-61. PubMed ID: 30425106
[TBL] [Abstract][Full Text] [Related]
8. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
9. DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity.
Wu J; Wang W; Zhang J; Zhou B; Zhao W; Su Z; Gu X; Wu J; Zhou Z; Chen S
Front Immunol; 2019; 10():2559. PubMed ID: 31736974
[TBL] [Abstract][Full Text] [Related]
10. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.
Wang C; Ding Y; Liu Y; Zhang Q; Xu S; Xia L; Duan H; Wang S; Ji P; Huang W; Zhao G; Cao Z; Shen H; Wang Y
Front Immunol; 2020; 11():576603. PubMed ID: 33329543
[TBL] [Abstract][Full Text] [Related]
11. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse.
Charneau J; Suzuki T; Shimomura M; Fujinami N; Mishima Y; Hiranuka K; Watanabe N; Yamada T; Nakamura N; Nakatsura T
Cancer Sci; 2022 Apr; 113(4):1113-1124. PubMed ID: 35122353
[TBL] [Abstract][Full Text] [Related]
12. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
Wagner C; Neumann F; Kubuschok B; Regitz E; Mischo A; Stevanovic S; Friedrich M; Schmidt W; Rammensee HG; Pfreundschuh M
Cancer Immun; 2003 Dec; 3():18. PubMed ID: 14677925
[TBL] [Abstract][Full Text] [Related]
13. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
[TBL] [Abstract][Full Text] [Related]
14. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
Peters HL; Tripathi SC; Kerros C; Katayama H; Garber HR; St John LS; Federico L; Meraz IM; Roth JA; Sepesi B; Majidi M; Ruisaard K; Clise-Dwyer K; Roszik J; Gibbons DL; Heymach JV; Swisher SG; Bernatchez C; Alatrash G; Hanash S; Molldrem JJ
Cancer Immunol Res; 2017 Apr; 5(4):319-329. PubMed ID: 28254787
[TBL] [Abstract][Full Text] [Related]
15. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
Müller M; Huber F; Arnaud M; Kraemer AI; Altimiras ER; Michaux J; Taillandier-Coindard M; Chiffelle J; Murgues B; Gehret T; Auger A; Stevenson BJ; Coukos G; Harari A; Bassani-Sternberg M
Immunity; 2023 Nov; 56(11):2650-2663.e6. PubMed ID: 37816353
[TBL] [Abstract][Full Text] [Related]
16. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.
Rodeberg DA; Nuss RA; Elsawa SF; Celis E
Clin Cancer Res; 2005 Jun; 11(12):4545-52. PubMed ID: 15958640
[TBL] [Abstract][Full Text] [Related]
17. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
18. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
[TBL] [Abstract][Full Text] [Related]
20. Novel HLA-A2 restricted antigenic peptide derivatives with high affinity for the treatment of breast cancer expressing NY-ESO-1.
Shi W; Tong Z; Qiu Q; Yue N; Guo W; Zou F; Zhou D; Li J; Huang W; Qian H
Bioorg Chem; 2020 Oct; 103():104138. PubMed ID: 32745760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]